secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001055726-25-000064
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INOVIO completes rolling BLA for INO-3107; Q3 net loss $45.5M, cash runway into Q2 2026
--------------------------------------------------------------------------------

- Completed rolling BLA submission for INO-3107 (RRP); priority review requested; potential FDA decision mid-2026.
- Net loss of $45.5M ($0.87/share) versus $25.2M loss a year ago; operating loss improved to $21.2M from $27.3M.
- Cash and short-term investments $50.8M as of Sept 30, 2025; estimated runway into Q2 2026 with Q4 cash burn ~$22M.
- R&D expenses fell to $13.3M from $18.7M; G&A expenses $7.9M down from $8.6M year-over-year.
- Phase 1 DMAb data for COVID-19 published in Nature Medicine; demonstrated durable antibody expression in humans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000105572625000064/0001055726-25-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000105572625000064/ino-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001055726-25-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer